AGAleksander A. Globenko

Aleksander A. Globenko

*This is an algorithmically generated author record based on publicly available information.

Aleksander A. Globenko has a total of 109 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparative efficacy and safety of Vespireit® and Arlevert® in the treatment of patients with functional dizziness: results of an open-label multicenter randomized phase IV clinical trial

    by V. A. Parfenov, M. V. Zamergrad, O. V. Kosivtsova, N. V. Lebedeva, A. L. Vladykin, A. A. Globenko, K. A. Ishchenko, В. А. Парфенов, М. В. Замерград, О. В. Косивцова, et al.

    Functional dizziness (FD) is one of the most common causes of chronic dizziness. Objective: a comparative assessment of the efficacy and safety of Vespireit® (buspirone), 15 mg prolonged-release tablets, versus Arlevert® tablets (cinnarizine 20 mg + dimenhydrinate 40 mg) in the treatment of patients with FD. Material and methods. The clinical trial (CT) included 160 patients with FD and scores on the Dizziness Handicap Inventory (DHI) ≥31 points and the Mean Vertigo Score (MVS) ≥1.5 points, who were randomized into two groups. Patients in group 1 (n=80) received Vespireit at a dose of 15 mg (1 tablet) once daily for 28 days. Patients in group 2 (n=80) received Arlevert 1 tablet 3 times daily for 28 days. Treatment was administered against a background of vestibular gymnastics exercises. The primary efficacy endpoint (PEE) was the change in mean MVS score at visit 1-3 (day 28±1) compared with baseline (visit 1-1, day 1). Secondary efficacy endpoints (SEEs) included assessment compared with baseline (visit 1-1, day 1): 1) change in mean MVS score by visit 1-2 (day 7±1); 2) change in the proportion of patients with a ≥50% reduction in mean DHI score by visit 1-3; 3) change in mean score on the numerical rating scale (NRS) by visits 1-2 (day 7±1) and 1–3 (day 28±1); 4) assessment by patient and physician of clinical improvement in proportions of patients and mean scores on the Clinical Global Impression Scale-Improvement Scale (CGI-I) by visits 1-2 (day 7±1) and 1-3 (day 28±1). In case of recurrence (exacerbation of dizziness symptoms), a second course of treatment with the study drugs and a similar assessment using the scales were performed. At the end-of-study visit (day 365±7 from visit 1-1), the proportion of patients with recurrence and the duration of the remission period were assessed. Safety criteria included assessment of adverse events (AEs), clinically significant deviations in vital signs, laboratory parameters, and electrocardiography (ECG) parameters. Results. Assessment of the PEE revealed no significant differences between the groups (p=0.0814); the lower limit of the 95% confidence interval (-0.07 points) did not exceed the non-inferiority margin (-0.3), thus demonstrating non-inferior efficacy of Vespireit compared with Arlevert. Assessment of most SEEs showed a statistically significant advantage of therapy in group 1 compared with group 2: reduction in mean MVS score by visit 1-2 (p=0.0427); proportion of responders with ≥50% reduction in mean DHI score by visit 1-3 (p=0.0433); reduction in mean NRS score by visits 1-2 (p=0.0230) and 1-3 (p=0.12244); proportion of responders with marked improvement (1 point) and considerable improvement (2 points) on CGI-I by visits 1-2 and 1-3 (patient assessment p=0.0453 and p=0.0481, p=0.0101 and p=0.8584; physician assessment p=0.0725 and p=0.0321, p=0.0169 and p=0.8622). A similar anti-relapse effect was established in groups 1 and 2 [proportion of patients without recurrence in group 1 – 94.87% (n=74), in group 2 – 93.67% (n=74; p=1.0000); duration of remission in group 1 – 359.14±38.08 days, in group 2 – 361.33±15.77 days (p=0.1798)]. A total of 84 AEs were recorded in 35 (21.88%) patients: 52 AEs in 18 (22.5%) patients in group 1 and 32 AEs in 17 (21.25%) in group 2. No significant difference was found between the groups in the number of patients with AEs (p=0.8483). During the CT, no serious adverse events (SAEs), fatal SAEs, or AEs leading to discontinuation of therapy were recorded. No clinically significant deviations from normal were observed in the assessment of vital and laboratory parameters or ECG parameters. Conclusion. Assessment of the PEE demonstrated non-inferior efficacy, and for a number of SEEs, superiority of therapy with Vespireit over therapy with Arlevert was established in reducing manifestations of FD. The drugs demonstrated a comparably high level of anti-relapse effect and a favorable safety profile.

  • Pharmacokinetic Parameters of a Combination Drug Containing Imidazolyl Ethylamide of Pentanedioic Acid and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] Malonic Acid Diamide in Healthy Volunteers

    by I. G. Gordeev, E. E. Il’Ina, N. D. Ovchinnikova, Y. A. Dzhurko, V. N. Shabrov, A. S. Kotrini, A. A. Globenko, A. V. Kapashin, M. A. Pasko, И. Г. Гордеев, et al.

    The aim of the study was to evaluate the pharmacokinetic parameters of escalating doses of a combination drug containing imidazolyl ethylamide of pentanedioic acid (IPA) and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] malonic acid diamide (XС9) in healthy volunteers. Material and methods . A phase I clinical study was conducted to investigate the pharmacokinetic parameters of the combination drug IPA + XС9 after single and subsequent multiple oral administration in healthy volunteers. Healthy volunteers were enrolled sequentially into three dose cohorts. Volunteers in Cohort 1 ( n = 6) received IPA + XС9 capsules containing 90 mg of IPA and 5 mg of XС9 (90 mg + 5 mg); volunteers in Cohort 2 ( n = 6) received capsules containing 90 mg IPA + 10 mg XC9 (90 mg + 10 mg); and volunteers in Cohort 3 ( n = 12) received capsules containing 90 mg IPA + 20 mg XC9 (90 mg + 20 mg). During the single-dose period, volunteers received one IPA + XC9 capsule corresponding to their dose cohort. Progression to multiple dosing and dose escalation were permitted only after the independent data monitoring committee (IDMC) reviewed the safety data. The washout period between the single-dose and multiple-dose periods was at least 7 days and no more than 21 days. Blood and urine samples were collected to determine the concentrations of the study drug’s active substances, IPA and XC9. Quantification of the active substances in plasma and urine was performed by high-performance liquid chromatography with tandem mass spectrometry (HPLC-MS/MS). Results . During the singledose period, a slight dose-dependent effect of XC9 on the plasma pharmacokinetic parameters of IPA was observed. At the highest studied dose of IPA + XС9 (90 mg + 20 mg), the C max and AUC 0–t for IPA were 301.37 ± 89.28 ng/mL and 1297.707 ± 469.535 ng × h/mL, respectively. During the single-dose period, the systemic exposure to XС9 in plasma increased in a dose-dependent manner. The highest C max and AUC 0–t values were observed at the 20 mg dose of XС9: 22.171 ± 8.644 ng/mL and 170.713 ± 48.346 ng × h/mL for C max and AUC 0–t , respectively. During the multiple-dose period, the C max, ss and AUC 0–τ for IPA after administration of the study drug at the 90 mg + 20 mg dose were 305.38 ± 120.43 ng/mL and 1426.108 ± 526.010 ng × h/mL, respectively, showing a weak dependence on the XС9 dose. The C max , ss and AUC 0–τ for XC9 at the maximum dose were 31.694 ± 8.491 ng/mL and 215.106 ± 59.871 ng × h/mL, respectively, demonstrating a dose-dependent increase. The pharmacokinetic parameters Ae (0–t) and R max , which reflect urinary excretion and maximum excretion rate, respectively, after a single dose of the study drug at the maximum dose were as follows: for IPA, 31390.317 ± 12193.271 µg and 5189.714 ± 2321.748 µg/h; and for XС9, 1054301.250 ± 452137.325 ng and 130015.240 ± 51728.662 ng/h. Regardless of the XС9 dose, the renal clearance of IPA remained constant during single dosing, ranging from 24 to 28 L/h, whereas the renal clearance of XС9 decreased with increasing doses (from 11.308 ± 4.111 L/h to 6.125 ± 1.430 L/h). In Cohort 3, during the multiple-dose period of IPA + XС9, the Ae (0–t) and R max values for IPA were 29563.529 ± 13674.235 µg and 4119.161 ± 2231.369 µg/h, and for XС9, they were 1671113.167 ± 733115.091 ng and 172748.875 ± 96684.186 ng/h, respectively. During the multiple-dose period, IPA renal clearance remained constant, ranging from 19 to 22 L/h, whereas XC9 renal clearance decreased with increasing doses. Conclusion . The study evaluated the plasma and urinary pharmacokinetics of IPA and XС9. A weak increase in IPA exposure was observed as the XС9 dose increased. Systemic exposure to XС9 increased in a dose-dependent manner in both the single-dose and multiple-dose periods. Regardless of the XС9 dose, the renal clearance of IPA remained constant, whereas the renal clearance of XС9 decreased with increasing doses. The results showed no significant pharmacokinetic interaction between IPA and XС9. Thus, the investigated combination of active substances meets current requirements for combination drug products.

  • Open Access

    Optimal Dosage Regimen of Grammidin® with Anesthetic in the Treatment of Acute Infectious Inflammatory Conditions of the Pharynx

    by O. V. Karneeva, A. V. Gurov, E. P. Karpova, T. I. Garashchenko, D. A. Tulupov, V. B. Vasilyuk, E. D. Volnaya, D. N. Alpenidze, М. А. Леонтьева, I. V. Gamova, et al.

    The aim of the study was to evaluate the efficacy and safety of two dosing regimens of Grammidin® with anesthetic (metered-dose oropharyngeal spray) in the treatment of acute infectious inflammatory conditions of the pharynx. Materials and methods . The study included a total of 222 patients presenting with sore throat as the predominant symptom, diagnosed with acute pharyngitis, acute nasopharyngitis, or acute exacerbation of chronic pharyngitis. Participants were randomized in a 1:1:1 allocation ratio to 3 parallel groups of equal size (N = 74 per group). Patients randomized to group 1 received Grammidin® with anesthetic (metered-dose oropharyngeal spray), 2 sprays every 6 hours (3 times daily) after meals; participants in group 2 received the same formulation, 4 sprays every 6 hours (3 times daily) after meals; and participants in group 3 received Septolete® Total (lozenges; benzydamine hydrochloride 3 mg and cetylpyridinium chloride 1 mg), 1 lozenge every 6 hours (3 times daily). The treatment duration was 7 days. Efficacy was assessed based on: reduction in sore throat intensity, measured using a visual analog scale (VAS); changes in symptom severity according to the Tonsillopharyngitis Clinical Scoring Scale; presence and severity of erythema and edema of the pharyngeal and tonsillar mucosa, as well as the severity of systemic intoxication symptoms. Results . Primary endpoint analysis (ITT population) confirmed a statistically significant dose-related effect of Grammidin® with anesthetic: the 4-spray regimen demonstrated greater reduction in VAS throat pain scores 60 minutes after the first administration in contrast with both comparators. Mean differences (rounded to 1 decimal place) were 9.29 mm in the Grammidin® with anesthetic 2-spray regimen group and 11.66 mm in the Septolete® Total group, respectively. By day 8, all patients demonstrated clinically significant improvement, with no statistically significant between-group differences ( P = 0.197). Per-protocol analysis on day 8 confirmed sustained symptomatic benefit of Grammidin® with anesthetic over Septolete® Total across both dose levels on the Tonsillopharyngitis Clinical Scoring Scale (2 sprays vs comparator: P = 0.008; 4 sprays vs comparator: P = 0.024), supporting a consistent clinical benefit. Conclusion . The 4-spray, 3-times-daily (after meals) regimen of Grammidin® with anesthetic for 7 days demonstrated a clinically relevant benefit over both the 2-spray regimen (3-times-daily after meals) and the active comparator, Septolete® Total (1 lozenge every 6 hours 3 times daily), in the treatment of acute infectious-inflammatory pharyngeal conditions. The safety profile of Grammidin® with anesthetic was consistent across dose levels, with no clinically important differences observed relative to Septolete® Total.

  • Open Access

    Pharmacokinetic and safety comparison of two dosage strengths of the drug Ranquilon®: a bioequivalence study

    by V. B. Vasilyuk, S. A. Sinyavin, A. A. Globenko, A. V. Kapashin, М. А. Пасько

    Aim. To evaluate the comparative pharmacokinetics, bioequivalence, and safety of the test product Ranquilon® 2 mg tablets and the reference drug Ranquilon®1 mg tablets in healthy volunteers under fed conditions. Material and methods. A randomized, open-label, comparative, two-period crossover study was conducted to evaluate the pharmacokinetic parameters, bioequivalence, and safety of two dosage strengths of the drug Ranquilon® — 1 mg tablets and 2 mg tablets. Thirty-six healthy volunteers were randomized into two sequence groups ( n =18 per group). Participants in group 1 (sequence RT) received two 1 mg tablets of Ranquilon® in period 1 and one 2 mg tablet of Ranquilon® in period 2. Participants in group 2 (sequence TR) received the study drugs in the reverse order. The washout period between dosing was 7 days. The plasma concentration of the active substance of Ranquilon® (amide N-(6-phenylhexanoyl)glycyl-L-tryptophan) was determined using a validated method of high-performance liquid chromatography–tandem mass spectrometry (HPLC-MS/MS). Vital sings, clinical laboratory parameters (complete blood count and biochemical blood analysis, urinalysis), and 12-lead electrocardiogram (ECG) data were monitored and evaluated during the study. All subjectreported complaints, as well as any deviations from reference ranges in volunteers’ clinical condition, laboratory tests results, and ECG parameters, were considered by the investigators as adverse events (AEs). Results. The mean maximum plasma concentration (C max ) was 8.00±3.67 ng/ml for the test product and 8.29±3.75 ng/ml for the reference drug. The mean area under the concentration-time curve (AUC 0-t ) was 18.91±7.49 ng × hr/ml for the test product, and 21.05±8.33 for the reference drug. The calculated 90 % confidence intervals (CI) for the mean ratios (test/reference) of C max and AUC 0-t were 83.36–107.74 % and 83.06–98.61 %, respectively. Both intervals fall within the predefined bioequivalence range of 80.00–125.00 %. A total of 22 adverse events (AEs) were reported in 13 volunteers. Eight AEs occurred in 5 volunteers (27.8 %) in group 1, and fourteen AEs in 8 volunteers (44.4 %) in group 2. All AEs were mild in severity, resolved spontaneously without sequelae, and required no therapeutic intervention or study-drug discontinuation. Conclusion. Bioequivalence between the test product Ranquilon® 2 mg tablets and the reference drug Ranquilon® 1 mg tablets was conclusively demonstrated at an equivalent dose of 2 mg of the active substance. Both products exhibited favorable and comparable safety profiles.

  • Study of the Pharmacokinetics, Tolerability, and Safety of Fixed-Dose Combinations of Gramicidin S and Cetylpyridinium Chloride

    by V. A. Dedkova, A. M. Bartsits, I. R. Khasanova, Yu. A. Dzhurko, L. N. Schitov, V. N. Shabrov, M. S. Zak, A. A. Globenko, A. V. Kapashin, M. A. Pasko

    The aim of the study was to compare the safety, tolerability, and pharmacokinetic profile of Grammidin® neo, lozenges, and Grammidin®, a metered-dose topical spray, manufactured by Valenta Pharm JSC, Russia, following single-dose administration in healthy volunteers. Material and methods. An open-label, randomized, two-period crossover study was conducted to evaluate the safety, tolerability, and pharmacokinetic parameters of Grammidin® (metered-dose topical spray) compared to Grammidin® neo (lozenges). Healthy volunteers were randomized into two sequence groups according to the order of drug administration in periods I and II of the study. In group 1, subjects received 1 lozenge of Grammidin® neo during period I. In period II, the same volunteers received 4 sprays of Grammidin® to the oral and pharyngeal mucosa applied by the researcher. Group 2 subjects received the study medications in reverse order. The washout period between administrations of the study drugs was 7 days. Concentrations of the active pharmaceutical substances were determined in plasma using high-performance liquid chromatography–tandem mass spectrometry (LC-MS/MS) with prior analyte extraction from the biological matrix. The study included ongoing monitoring of vital signs, as well as assessments of laboratory parameters (complete blood count, serum biochemistry, and urinalysis) and standard 12-lead ECG recordings. All subject-reported complaints, as well as any abnormalities or clinically significant deviations from reference ranges in general health status, laboratory findings, or ECG parameters were documented and categorized by the researcher as adverse events (AEs ). Results . Of the 16 volunteers who received the study drugs in periods I and II, only 6 demonstrated plasma concentrations of gramicidin S and cetylpyridinium chloride above the lower limit of quantification (LLOQ) at isolated time points. Due to the insufficient number of measurable concentrations, pharmacokinetic parameters could not be reliably calculated. During the study, one mild adverse event (AE) was reported in a single volunteer — pain at the catheter insertion site. The relationship between this AE and study drug administration was assessed by the researcher as indeterminate. This AE resolved spontaneously without any therapeutic intervention. Conclusion . Topical administration of gramicidin S and cetylpyridinium chloride to the oropharyngeal mucosa resulted in minimal systemic exposure, making pharmacokinetic characterization unfeasible. The fixed-dose combination was safe and well tolerated in all participants, with no meaningful differences observed between the lozenge and spray formulations.

  • Open Access

    Evaluation of the pharmacological effect of Antareit® (oral suspension, 800 mg/10 ml) in healthy volunteers

    by K. A. Zakharov, V. B. Vasilyuk, A. S. Goncharov, V. S. Arnautov, A. A. Globenko, A. V. Kapashin, М. А. Пасько

    The aim of the study was to evaluate the pharmacodynamic equivalence of the drugs Antareit® (oral suspension, 800 mg/10 ml; Valenta Pharm JSC, Russia) and Riopan® (chewable tablets, 800 mg; Takeda GmbH, Germany) based on their antacid activity.Material and methods. An open-label, two-period two-sequence crossover study was conducted to evaluate the pharmacodynamics of the test drug Antareit® (oral suspension, 800 mg/10 ml) and the reference drug Riopan® (chewable tablets, 800 mg), both administered as a single oral dose of 1600 mg. A total 50 healthy volunteers were randomized into two groups (n = 25) according to treatment sequence with a 7-day washout period between administrations. Gastric pH was continuously monitored for 1 hour after dosing using an intragastric pH probe placed in the gastric corpus. The main pharmacodynamics parameter was the area under the pH-time curve above baseline (AUCABL). Equivalence was determined by calculating the 90 % confidence interval (CI) for the ratio of marginal means of AUCABL between the two formulations. Safety was assessed through monitoring of adverse events (AEs), physical examinations, vital signs measurement, laboratory tests and electrocardiogram (ECG) findings.Results. A total of 48 out of 50 randomized subjects completed both periods of the study. Two volunteers discontinued before receiving the drug in period 2. The 90 % CI for the AUCABL was calculated using a mixed-effects model (MIXED) and a generalized linear model (GLM). The marginal mean AUCABL values were 68,81 for Antareit®, oral suspension, 800 mg/10 ml and 68,42 for Riopan®, chewable tablets, 800 mg based on GLM analysis. The AUCABL ratio (test drug / reference drug) was 100,57 % (90 % Cl: 82,44–122,69 %), indicating non-inferiority. Three AEs occurred in two subjects: two cases of rhinorrhea in one volunteer and one case of somnolence following drug administration. There were no statistically significant differences in the frequency of AEs between treatments.Conclusion. The study established pharmacodynamic equivalence between the test drug Antareit®, oral suspension, 800 mg/10 ml and the reference drug Riopan®, chewable tablets, 800 mg. The safety profiles of both treatments were found to be similar, with no significant differences observed in either the incidence or severity of AE.

  • Open Access

    Study of the Safety and Toxicokinetic Parameters of the Drug Eladis® in Preclinical Trials with Repeated Administration

    by M. V. Miroshnikov, A. A. Matichina, V. M. Kosman, M. V. Karlina, E. M. Petrova, A. A. Globenko, E. A. Jain, A. V. Kapashin, A. L. Vladykin, A. S. Kolosov, et al.

    Cough is one of the most common reasons for initial visits to healthcare providers, affecting 40–50% of patients with viral respiratory tract infections. Treatment options for cough include medications that block signal transmission at the central or peripheral level of the reflex arc, as well as mucolytic and expectorant agents. Valenta Pharm JSC has developed an innovative drug, Eladis® (film-coated tablets, 20 mg and 40 mg), intended for the treatment of cough in patients with acute respiratory infections. The aim of the present study was to assess the safety profile and toxicokinetic parameters of the drug after repeated administrations. In the study conducted on mature rabbits, the drug was administered orally at doses of 1, 3, or 6 tablets/animal over 28 days, corresponding to 13.3, 40, and 80 mg/kg, respectively. No signs of intoxication were observed in any of the experimental groups. To evaluate toxicokinetic parameters, blood samples were collected from the marginal ear vein after the 1st and 28th days of administration. Both single and multiple (28-day) administrations of the drug showed a statistically significant increase in Cmax and AUC0–24 with increasing doses. No drug accumulation was observed following repeated administration on day 28. In a separate study on juvenile rats, Eladis® was administered intragastrically for 30 days at doses of 11.8, 118, and 236 mg/kg. The results indicated no significant effects of the drug on body weight gain, animal behavior in a battery of functional tests, as well as the estimated physiological, biochemical, and hematological parameters. The drug demonstrated no local irritant or immunotoxic effects and had no impact on spermatogenesis.

  • Open Access

    Evaluation of Efficacy and Safety of Different Doses of Eladis® in the Therapy of Cough Against Acute Respiratory Viral Infection

    by E. D. Volnaya, S. V. Teplykh, V. V. Popova, O. A. Vasilevskaya, E. A. Polyakova, S. E. Ushakova, V. B. Shunkov, A. A. Globenko, A. V. Kapashin, М. А. Пасько

    Aim. Justification of the optimal dosage regimen regarding the efficacy and safety of Eladis®, film-coated tablets, 10 mg (Valenta Pharm JSC, Russia) in comparison with placebo in patients with non-productive cough due to acute respiratory viral infection (ARVI). Material and methods. A double-blind placebo-controlled randomized multicenter study was conducted in which 141 patients with non-productive cough on the background of acute respiratory viral infection took part. The study participants were randomized into 4 groups. Patients from the first group took 1 tablet of Eladis® 2 times a day (daily dose of 20 mg); patients from the second group took 2 tablets of Eladis® 2 times a day (daily dose of 40 mg); patients from the third group took 4 tablets of Eladis® 2 times a day (daily dose of 80 mg). Patients in the fourth group received placebo tablets in quantities corresponding to the first three groups. For this purpose, 3 subgroups of 12 people were allocated within group 4. The duration of therapy was 7–14 days. The effectiveness of therapy was assessed based on monitoring the frequency of cough attacks, changes in values on the day and night cough scales, a digital rating scale (DRS), and the time to achieve clinical cure of cough and ARVI symptoms was also taken into account. The safety of the studied drug was assessed based on monitoring of vital signs, laboratory parameters, and electrocardiogram (ECG) data. The number and severity of adverse events (AEs) and serious adverse events (SAEs) were assessed. Results. Analysis of data on the primary endpoint (reduction of cough attack frequency by ;)50% by the 5th day relative to the 1st visit) showed the superiority of Eladis® over placebo at a daily dose of 80 mg (P=0.00003). At the same time, the proportion of patients who reached the primary endpoint by day 5 when receiving Eladis® at a dose of 80 mg per day was 71.43%, while in the combined placebo group it was 22.22%. Conclusion. Evaluation of various dosage regimens of Eladis® has shown that a daily dose of 80 mg is optimal for the treatment of non-productive cough in patients with ARVIs, as it provides the greatest effectiveness with a safety profile comparable to other studied doses.

  • Open Access

    Study of pharmacokinetic parameters and safety of the drug Duonica® in comparison with the original combination of doxylamine and pyridoxine under fed conditions

    by I. E. Shohin, S. M. Noskov, A. A. Globenko, N. S. Bagaeva, K. K. Karnakova, O. M. Parulya, L. N. Lutskova, A. V. Kapashin, М. А. Пасько

    Aim. A comparative study of the pharmacokinetics and safety of the investigational drug Duonica®, enteric-soluble, film-coated tablets, 10 mg + 10 mg (Valenta Pharm JSC, Russia) and the reference drug Diclectin®, delayed-release tablets, 10 mg + 10 mg (Duchesnay Inc, Canada) was conducted as part of the bioequivalence study in healthy volunteers under fed conditions.Material and methods. An open-label randomized crossover two-period bioequivalence study was conducted with 28 Caucasian female volunteers. The study participants were randomly divided into two groups of 14 people depending on the order of drug administration during Periods 1 and 2. Participants randomized to the first group received 2 tablets of Diclectin® during Period 1 and 2 tablets of Duonica® during Period 2. Volunteers from the second group took the study drugs in the reverse order. During each study Period, the drugs were administered after a high-calorie breakfast. The analytes studied were doxylamine and pyridoxal-5-phosphate (an active metabolite of pyridoxine). Methods were developed and validated using high-performance liquid chromatography with a triple quadrupole tandem mass spectrometric detector (HPLC-MS/MS) to quantify the analytes. Pharmacokinetic parameters were calculated from the obtained concentration values and statistical analysis was performed. To confirm bioequivalence, 90 % confidence intervals (CI) for the pharmacokinetic parameters AUC and Cmax of the studied analytes were calculated. The safety of the investigational drugs was assessed based on the frequency, severity and type of adverse events.Results. The 90 % CI values for the ratio of Cmax and AUC(0-t) values for doxylamine were 94.08–113.71 % and 90.63–102.50 %, and for pyridoxal-5-phosphate were 97.34–123.47 % and 90.30–111.03 %, respectively. The obtained CI values were within the limits set by the regulatory requirements and the study protocol (80.00–125.00 %), which allowed us to confirm the bioequivalence of the studied drugs for both components. No adverse events were reported during the study.Conclusion. The study investigated the pharmacokinetics of drugs containing a fixed combination of doxylamine and pyridoxine under fed conditions. The results obtained confirmed the bioequivalence of the drug Duonica® to the reference drug Diclectin®. Both drugs were well tolerated and no differences in the safety profile of the investigational drugs were observed.

  • Open Access

    Study of the Pharmacokinetics and Safety of Dioxidine®, Solution for Topical and External Use, 0.25 mg/ml, in Various Routes of Administration

    by V. A. Stepanov, S. V. Ponasenkova, E. S. Simonova, P. D. Sobolev, A. G. Nikiforova, A. A. Globenko, A. V. Kapashin, М. А. Пасько

    Topical use of antibacterial drugs as part of complex therapy for purulent-inflammatory infections of the skin and oropharynx can not only eliminate the symptoms but also influence the cause of the disease. Dioxidine® is a broad-spectrum antibacterial drug, active against both gram-positive and gram-negative bacteria. The aim of this study was to investigate the bioavailability, pharmacokinetic parameters, and safety profile of Dioxidine®, solution for topical and external use, 0.25 mg/ml, in cutaneous and topical application. Another dosage form of Dioxidine® — a solution for infusion and external use, 5 mg/ml — was used as a comparison drug. The study consisted of 4 stages reflecting different routes of drug administration: rinsing the oropharynx (path A), a single irrigation of the oropharynx using a spray nozzle (path B), back skin irrigation (path C), and intravenous administration (path D — for the reference drug). The results of the study made it possible to determine the absolute dose-normalized bioavailability of the study drug in the indicated routes of administration, as well as to evaluate its safety profile.